F115 - Management Issues in Cutaneous Lymphoma
Sunday, February 18; 3:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Apply appropriate tools and tests to diagnose challenging cases of cutaneous lymphoma and to distinguish from its mimics.
- Identify and formulate an optimal management strategy personalized for the patient
- Discuss how the prescribed management benefited and potentially harmed the patient and how it can be modified to further improve your clinical practice
Cutaneous lymphoma is a group of rare disorders with quite heterogeneous presentations, where management should be individualized to optimize the overall benefit. This session will focus on the critical assessment of how we can improve our clinical management by using cases provided by experts. The participants will enjoy the discussion on utilizing cost-effective tools/tests for diagnosis, optimizing diagnosis by appropriate clinical-pathologic interpretation, developing a personalized management program, and evaluating the clinical outcome of the selected management. Each case discussion will conclude with how the management can be improved to deliver the optimal care for the patient with cutaneous lymphoma.
- Duvic, Madeleine, MD: American Council on Extracorporeal Photopheresis (ACE) – A(H); Clinical Care Options – C(NC); Concert Pharmaceuticals – C(NC); Cutaneous Lymphoma Foundation – A(NC); Defined Health – C(NC); Eisai Pharmaceuticals – C(H), SP(H); George Washington University – SP(H); Guidepoint Global, LLC – C(NC); Huron Consulting Group – C(H); Innate Pharma S.A. – C(H); Jonathan Wood & Associates – SP(NC); Kiniksa Pharmaceuticals, Ltd. – C(H); Kyowa Hakko Kirin Pharma, Inc. – C(H); MEDACorp – C(H); Medscape – SP(H); Millennium Pharmaceuticals – C(H); Millennium Pharmaceuticals, Inc. – Data Safety Monitoring Board(H); miRagen Therapeutics, Inc. – C(H); Oklahoma University Dermatology Grand Rounds – SP(H); OncLive State of the Science Summit – SP(H); Precision Oncology, LLC – A(H); Seattle Genetics – A(H); Soligenix, Inc – A(H); The Mastocytosis Society – A(NC); USCLC Registry – C(NC);
- Geskin, Larisa J., MD: Actelion – Speaker/Faculty Education(H); Mallinckrodt Pharmaceuticals – C(H);
- Guitart, Joan, MD: Actelion – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – A(Fees); Soligenix, Inc – I(Grants/Research Funding); Tetralogic Pharmaceuticals – I(Grants/Research Funding);
- Kim, Youn H., MD: Eisai Pharmaceuticals – A(H), I(Grants/Research Funding); Forty Seven Inc. – I(Grants/Research Funding); Horizon Pharma, Inc. – I(Grants/Research Funding); Innate Pharma, S.A. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), I(OB); Merck & Co., Inc. – I(Grants/Research Funding); Millennium Pharmaceuticals – A(H), I(OB); miRagen Therapeutics, Inc. – I(Grants/Research Funding); Neumedicine, Inc. – I(Grants/Research Funding); Portola Pharmaceuticals, Inc. – I(Grants/Research Funding); Seattle Genetics – C(H); Soligenix, Inc – I(Grants/Research Funding);
- Novoa, Roberto, MD: Novan – SH(ST); Zebra Medical Technologies, Inc. – C(Fees);
- Pincus, Laura, MD: no financial relationships exist with commercial interests.
- Rook, Alain H., MD: Galderma USA – I(IP);
Sunday, February 18
Dr. Kim / Overview
Dr. Novoa / IgG4-related disease and cutaneous lymphoid infiltrates: Puzzles and Pitfalls
Dr. Rook / Management of folliculotropic mycosis fungoides
Dr. Duvic / Management of transformed mycosis fungoides
Dr. Geskin / Management challenges in Sézary syndrome
Dr. Pincus / Management issues in children with MF
Dr. Guitart / Allogeneic transplants in CTCL: alternative donor sources and clinical outcome
Dr. Kim / Management of toxicities of newer therapies in CTCL
Dr. Kim, Dr. Novoa, Dr. Rook, Dr. Duvic, Dr. Pincus, Dr. Guitart, and Dr. Geskin / Final remarks